Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Medicover Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Fredrik Rågmark

İcra Kurulu Başkanı

€2.7m

Toplam tazminat

CEO maaş yüzdesi	39.2%
CEO görev süresi	27.8yrs
CEO sahipliği	1.0%
Yönetim ortalama görev süresi	4.2yrs
Yönetim Kurulu ortalama görev süresi	15.3yrs

Son yönetim güncellemeleri

Recent updates

Investors Appear Satisfied With Medicover AB (publ)'s (STO:MCOV B) Prospects

Apr 22

Additional Considerations Required While Assessing Medicover's (STO:MCOV B) Strong Earnings

Apr 04

Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet

Mar 05

Medicover AB (publ)'s (STO:MCOV B) Intrinsic Value Is Potentially 31% Above Its Share Price

Feb 11

Is There An Opportunity With Medicover AB (publ)'s (STO:MCOV B) 37% Undervaluation?

Jun 12

Medicover (STO:MCOV B) Will Want To Turn Around Its Return Trends

May 27

Is Medicover (STO:MCOV B) Using Too Much Debt?

May 12

Returns On Capital At Medicover (STO:MCOV B) Have Hit The Brakes

Feb 16

Is Medicover (STO:MCOV B) Using Too Much Debt?

Jan 30

Is Medicover AB (publ) (STO:MCOV B) Potentially Undervalued?

Dec 30

Estimating The Fair Value Of Medicover AB (publ) (STO:MCOV B)

Dec 17

Medicover (STO:MCOV B) Might Have The Makings Of A Multi-Bagger

Oct 30

Does Medicover (STO:MCOV B) Have A Healthy Balance Sheet?

Oct 16

Should You Think About Buying Medicover AB (publ) (STO:MCOV B) Now?

Sep 09

Estimating The Intrinsic Value Of Medicover AB (publ) (STO:MCOV B)

Jul 25

Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet

Jul 12

Investors Met With Slowing Returns on Capital At Medicover (STO:MCOV B)

Jun 13

At kr179, Is It Time To Put Medicover AB (publ) (STO:MCOV B) On Your Watch List?

May 29

With EPS Growth And More, Medicover (STO:MCOV B) Is Interesting

Apr 20

CEO Tazminat Analizi

Fredrik Rågmark'un ücretlendirmesi Medicover'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	€23m
Mar 31 2024	n/a	n/a	€22m
Dec 31 2023	€3m	€1m	€18m
Sep 30 2023	n/a	n/a	€8m
Jun 30 2023	n/a	n/a	€5m
Mar 31 2023	n/a	n/a	€1m
Dec 31 2022	€3m	€1m	€12m
Sep 30 2022	n/a	n/a	€37m
Jun 30 2022	n/a	n/a	€59m
Mar 31 2022	n/a	n/a	€88m
Dec 31 2021	€2m	€952k	€102m
Sep 30 2021	n/a	n/a	€93m
Jun 30 2021	n/a	n/a	€90m
Mar 31 2021	n/a	n/a	€52m
Dec 31 2020	€2m	€670k	€26m
Sep 30 2020	n/a	n/a	€14m
Jun 30 2020	n/a	n/a	€4m
Mar 31 2020	n/a	n/a	€16m
Dec 31 2019	€1m	€900k	€23m
Sep 30 2019	n/a	n/a	€19m
Jun 30 2019	n/a	n/a	€19m
Mar 31 2019	n/a	n/a	€20m
Dec 31 2018	€1m	€807k	€22m
Sep 30 2018	n/a	n/a	€28m
Jun 30 2018	n/a	n/a	€26m
Mar 31 2018	n/a	n/a	€23m
Dec 31 2017	€921k	€810k	€19m

Tazminat ve Piyasa: Fredrik 'nin toplam tazminatı ($USD 3.00M ), Swedish pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.02M ).

Tazminat ve Kazançlar: Fredrik 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Fredrik Rågmark (61 yo)

27.8yrs

Görev süresi

€2,707,000

Tazminat

Mr. Fredrik Ragmark serves as the Chief Executive Officer of Medicover AB (publ). Mr. Ragmark has been employed with Medicover since 1996. He serves as Managing Director and Board Member of Kalvskär AB.Fr...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Fredrik Rågmark	CEO & Director	no data	€2.71m	1.04% € 293.4m
Jaroslaw Urbanczyk	Chief Information Officer	5yrs	Veri yok	0.0052% € 1.5m
Hanna Bjellquist	Head of Investor Relations	no data	Veri yok	Veri yok
Jenny Brandt	General Legal Counsel	no data	Veri yok	0.031% € 8.7m
Andrew Vallance-Owen	Chief Marketing Officer	no data	Veri yok	Veri yok
Kamila Skorupinski	Group Chief People Officer	less than a year	Veri yok	Veri yok
John Stubbington	Chief Operating Officer of Healthcare Services	8.7yrs	Veri yok	0.53% € 149.1m
Staffan Ternstrom	Chief Operating Officer for Diagnostic Services	3.3yrs	Veri yok	0.033% € 9.4m

4.2yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: MCOV B 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Fredrik Rågmark	CEO & Director	27.8yrs	€2.71m	1.04% € 293.4m
Robert Jochnick	Independent Director	17.8yrs	€54.60k	1.21% € 341.3m
Fredrik Stenmo	Independent Chairman	19.8yrs	€101.50k	4.41% € 1.2b
Margareta Nordenvall	Independent Director	23.8yrs	€66.20k	0.060% € 16.9m
Arno Bohn	Independent Director	23.8yrs	€63.05k	0.20% € 56.3m
Cecil Michael Flemming	Independent Director	9.8yrs	€78.30k	Veri yok
Anne Berner	Independent Director	2.5yrs	€59.85k	Veri yok
Azita Shariati	Independent Director	2.5yrs	€63.05k	0.0015% € 414.0k
Peder Jochnick	Independent Director	12.8yrs	€54.60k	2.59% € 728.7m
Sonali Chandmal	Independent Director	7.8yrs	€71.45k	0.017% € 4.7m

15.3yrs

Ortalama Görev Süresi

60.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MCOV B 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 15.3 yıldır).

Medicover Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Medicover AB (publ) Announces Nomination Committee for the AGM 2025

Medicover AB (publ), Annual General Meeting, Apr 25, 2025

Medicover AB (publ) Appoints Anand Patel as Chief Financial Officer, Effective October 1, 2024

General Legal Counsel recently sold kr1.2m worth of stock

Medicover Appoints Kamila Skorupinski as Chief People Officer as of 1 April 2024

Independent Chairman recently bought kr3.9m worth of stock

Recent updates

Medicover AB (publ) Announces Nomination Committee for the AGM 2025

Medicover AB (publ), Annual General Meeting, Apr 25, 2025

Medicover AB (publ) Appoints Anand Patel as Chief Financial Officer, Effective October 1, 2024

Second quarter 2024 earnings released: EPS: €0.042 (vs €0.037 in 2Q 2023)

Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025

General Legal Counsel recently sold kr1.2m worth of stock

Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025

First quarter 2024 earnings released: EPS: €0.041 (vs €0.01 in 1Q 2023)

Upcoming dividend of €0.12 per share

Investors Appear Satisfied With Medicover AB (publ)'s (STO:MCOV B) Prospects

Additional Considerations Required While Assessing Medicover's (STO:MCOV B) Strong Earnings

New minor risk - Earnings quality

Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet

Dividend of €0.12 announced

Medicover AB (publ)'s (STO:MCOV B) Intrinsic Value Is Potentially 31% Above Its Share Price

Full year 2023 earnings: EPS exceeds analyst expectations

Now 24% undervalued

Medicover AB (publ) Provides Earnings Guidance for the Financial Year 2025

Medicover Appoints Kamila Skorupinski as Chief People Officer as of 1 April 2024

Consensus EPS estimates increase by 27%

Returns On Capital At Medicover (STO:MCOV B) Paint A Concerning Picture

Does Medicover (STO:MCOV B) Have A Healthy Balance Sheet?

Independent Chairman recently bought kr3.9m worth of stock

New minor risk - Earnings quality

Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025

Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025

Medicover AB (Publ) Announces Resignation of Joe Ryan as Chief Financial Officer

Independent Director recently bought kr303k worth of stock

Medicover AB (publ) Announces Nomination Committee for the Annual General Meeting 2024

Medicover AB (publ), Annual General Meeting, Apr 26, 2024

Medicover's (STO:MCOV B) Returns On Capital Not Reflecting Well On The Business

Medicover (STO:MCOV B) Has A Somewhat Strained Balance Sheet

Independent Director recently bought kr1.4m worth of stock

Independent Chairman recently bought kr6.3m worth of stock

Second quarter 2023 earnings released: EPS: €0.037 (vs €0.01 in 2Q 2022)

Medicover AB (publ) to Report Q1, 2024 Results on Apr 26, 2024

Insider recently bought kr242k worth of stock

Is There An Opportunity With Medicover AB (publ)'s (STO:MCOV B) 37% Undervaluation?

Chief Information Officer recently bought kr321k worth of stock

Medicover (STO:MCOV B) Will Want To Turn Around Its Return Trends

Is Medicover (STO:MCOV B) Using Too Much Debt?

Consensus EPS estimates fall by 10%

Now 21% undervalued after recent price drop

Upcoming dividend of €0.12 per share at 0.7% yield

Full year 2022 earnings: Revenues in line with analyst expectations

Consensus EPS estimates fall by 72%

Now 23% undervalued

Full year 2022 earnings: Revenues in line with analyst expectations

Medicover AB (publ) Proposes Dividend for 2022

Returns On Capital At Medicover (STO:MCOV B) Have Hit The Brakes

Consensus EPS estimates fall by 26%

Is Medicover (STO:MCOV B) Using Too Much Debt?

Investor sentiment improved over the past week

Is Medicover AB (publ) (STO:MCOV B) Potentially Undervalued?

Estimating The Fair Value Of Medicover AB (publ) (STO:MCOV B)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues exceed analyst expectations

Medicover AB (publ) to Report Q2, 2023 Results on Jul 26, 2023

Medicover (STO:MCOV B) Might Have The Makings Of A Multi-Bagger

Medicover AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Does Medicover (STO:MCOV B) Have A Healthy Balance Sheet?

Medicover AB (publ) (OM:MCOV B) acquired Übag Mvz Meindentist Gbr.

Medicover AB (publ) (OM:MCOV B) completed the acquisition of Laurus Medical SRL.

Medicover AB (publ), Annual General Meeting, Apr 27, 2023

Should You Think About Buying Medicover AB (publ) (STO:MCOV B) Now?

Estimating The Intrinsic Value Of Medicover AB (publ) (STO:MCOV B)

Second quarter 2022 earnings: Revenues exceed analyst expectations

Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet